DUBLIN--(BUSINESS WIRE)--The "Type 2 Angiotensin II Receptor - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Type 2 Angiotensin II Receptor - Pipeline Review, H1 2020, outlays comprehensive information on the Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene. AT2 receptor is highly expressed in the developing foetus, but its expression is very low in the cardiovascular system of the normal adult. Expression of the AT2 receptor can be modulated by pathological states associated with tissue remodeling or inflammation such as hypertension, atherosclerosis, and myocardial infarction. AT2 receptor plays an important role in vasodilatory role, and enhanced as a countervailing mechanism in cardiac hypertrophy, and in presence of vascular injury in hypertension and atherosclerosis.
The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 3, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. The report covers products from therapy areas Cardiovascular, Central Nervous System, Dermatology, Gastrointestinal, Respiratory, Genito Urinary System And Sex Hormones, Immunology, Infectious Disease, Metabolic Disorders, Musculoskeletal Disorders, Oncology and Women's Health which include indications Idiopathic Pulmonary Fibrosis, Atherosclerosis, Cardiomyopathy, Coronavirus Disease 2019 (COVID-19), Diabetic Neuropathic Pain, Fibrosis, Hyperlipidemia, Hypertension, Inflammatory Pain, Kidney Fibrosis, Liver Fibrosis, Myocardial Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Polycystic Ovarian Syndrome, Postherpetic Neuralgia, Skin Inflammation, Systemic Sclerosis (Scleroderma) and Wounds.
Furthermore, this report also reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Key Topics Covered:
- Introduction
- Report Coverage
- Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Overview
- Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Companies Involved in Therapeutics Development
- Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Drug Profiles
- (amlodipine besylate + valsartan) + atorvastatin calcium - Drug Profile
- KDT-501 - Drug Profile
- MOR-107 - Drug Profile
- NP-6A - Drug Profile
- olodanrigan - Drug Profile
- Small Molecule to Antagonize AGTR2 for Skin Inflammation and Inflammatory Pain - Drug Profile
- Small Molecules to Agonize AGTR2 for Fibrosis - Drug Profile
- Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile
- VP-01 - Drug Profile
- VP-02 - Drug Profile
- Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Dormant Products
- Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Discontinued Products
- Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Product Development Milestones
- Featured News & Press Releases
- Mar 31, 2020: Vicore Pharma submits Letter of Intent for a clinical trial application for a phase II study in patients with COVID-19, SARS CoV-2 infection
- Mar 30, 2020: Vicore submits clinical trial application for phase II trial with C21 in IPF
- Dec 18, 2019: Update on progress for drug development program VP02 (IMiD)
- Dec 18, 2019: Update on progress for drug development program VP01 (C21)
- Oct 01, 2019: Update on progress in clinical lead program VP01 (C21)
- Sep 06, 2019: Safe and well tolerated dose of C21 established in successful dose escalation phase 1 study
- Apr 23, 2019: Vicore Pharma announces systemic sclerosis as the second indication for VP01
- Sep 10, 2018: Vicore Pharma expands VP01 (C21) clinical program to enable functional read out
- Jul 05, 2018: Non-opioid drug relieves pain in mice, targets immune cells
- Apr 18, 2018: Vicore Pharma receives approval to start Phase IIa study in IPF
- Mar 21, 2018: Frontiers in Physiology publish data with C21 on pulmonary fibrosis
- Jan 26, 2018: Highlights from new publications on C21 and the AT2 receptor
- Dec 22, 2017: Vicore Pharma has submitted an application to start a phase II study for Idiopathic Pulmonary Fibrosis
- Oct 09, 2017: Clinical Potential of C21 Highlighted in Review Publications
- Oct 02, 2017: Phase I extension study demonstrates beneficial effects on lipid metabolism with C21
Companies Mentioned
- CJ HealthCare Corp
- KinDex Pharmaceuticals Inc
- MorphoSys AG
- Novartis AG
- Novopyxis Inc
- Vicore Pharma AB
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/vebk79
